Skip to main content

MRC, Renishaw Dx Partner on Infectious Disease Tests

NEW YORK (GenomeWeb News) – MRC Technology today announced a collaboration with Renishaw Diagnostics to identify and develop clinical diagnostic tests for infectious diseases.

The collaboration combines Renishaw's multiplex screening technology and expertise in assay development with MRC's experience in developing early-stage research for clinical applications and commercialization, MRC said. The focus will be on identifying and accelerating research with potential in infectious disease diagnostics.

Renishaw's RenDx multiplex assay system is based on surface enhanced resonance Raman scattering, and provides automated, multiplex, in vitro screening for clinical research.

Financial and other terms of the agreement were not disclosed.

"MRC Technology's expertise and experience will allow us to accelerate development of our assay portfolio, enhancing the capabilities of the RenDx platform and providing end users with additional value and flexibility," Renishaw General Manager Rupert Jones said in a statement.

MRC is a London-based technology transfer organization. Renishaw Diagnostics, a subsidiary of the Renishaw Group, is based in Glasgow, Scotland.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.